$CPIX News
Last published 1d ago
- 1d agoCPIXCUMBERLAND PHARMACEUTICALS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoCPIXCUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATEPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases,...
- 2w agoCPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAMPR NewswireNASHVILLE, Tenn., Oct. 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for
- 2w agoCPIXCumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line ResultsPR NewswireIfetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-driven biopharmaceutical company advancing
- 2w agoCPIXCUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALLPR NewswireNASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs,
- 3mo agoCPIXCUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTSPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial...
- 3mo agoCPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTSPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare...
- 4mo agoCPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHAREPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced...
- 4mo agoCPIXCumberland Pharmaceuticals Closes Strategic Transaction with ApotexPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of...
- 4mo agoCPIXCumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual ConferencePR NewswireCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare...
- 4mo agoRDHLCPIXRedHill Biopharma Announces Up To $19.4 Million Private PlacementPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a ...
- 5mo agoRDHLCPIXRedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug DesignationPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Food and...
- 5mo agoRDHLCPIXRedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against KukboPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has commenced...
- 5mo agoCPIXCumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer MetastasisPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, and...
- 5mo agoRDHLCPIXRedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense PlatformsPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it is actively...
- 5mo agoCPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINAPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ®...
- 6mo agoCPIXCUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATEPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands ...
- 6mo agoRDHLCPIXRedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's DiseasePR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new in vitro testing...
- 6mo agoCPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATEPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026...
- 6mo agoCPIXRDHLRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full-year 2025...
- 6mo agoCPIXCumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with ApotexPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an...
- 6mo agoRDHLCPIXRedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026PR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the independent...
- 6mo agoCPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITEPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and...
- 7mo agoCPIXCumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and VomitingPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso® (granisetron...
- 8mo agoRDHLCPIXPHATH. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsightPR NewswireRecently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori...
- 8mo agoCPIXCUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTHPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands ...
- 8mo agoRDHLCPIXJoint U.S. Commercialization of RedHill's Talicia® CommencesPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the full sales and...
- 8mo agoCPIXCUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®PR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today...
- 8mo agoCPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATEPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results...
- 9mo agoCPIXCumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy ProgramPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced...
- 11mo agoCPIXCALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENTPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection. The product's...
- 1y agoCPIXCUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTHPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands ...
- 1y agoCPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATEPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2025...
- 1y agoCPIXRDHLCUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIOPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient...
- 1y agoCPIXRDHLRedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership DealPR NewswireRedHill Biopharma Limited (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a...
- 1y agoCPIXCUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.PR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® (telavancin), to a...
- 1y agoCPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICOPR NewswireCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that its ibuprofen injection product, has...
- 1y agoCPIXTABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIAPR NewswireSpecialty pharmaceutical companies Tabuk Pharmaceutical Manufacturing Company a fully owned subsidiary of Astra Industrial Group and a leading...
- 1y agoABPCPIXXFORSitryx appoints Adam Mostafa as Chief Financial OfficerGlobeNewswireSitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8
- 1y agoCPIXCumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCPIXCumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-DatePR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands ...
- 1y agoCPIXCUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAKPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient...
- 1y agoCPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATEPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2025...
- 1y agoCPIXCumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual ConferencePR NewswireCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company committed to developing new products for rare diseases, shared the ...
- 1y agoCPIXNEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTSPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the publication of its study investigating...
- 1y agoCPIXCUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCHPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare...
- 1y agoCPIXCumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025PR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands ...
- 1y agoCPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATEPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025...
- 1y agoCPIXFIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific ConferencePR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced ...
- 1y agoCPIXCumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue GrowthPR NewswireCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands ...